TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03645499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TA-102 A
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TA-102 B
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TA-102 C
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TA-102 D
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TA-102 E
Description: applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
Study: NCT02970552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Progesterone
Description: 200 mg micronized vaginal progesterone suppository

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Indistinguishable placebo vaginal suppository
Study: NCT00071084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: HuMax-CD4 980 mg was administered as a SC infusion OD up to 16 weeks.
Study: NCT00977548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
Study: NCT02907099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXCR4 Antagonist BL-8040
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04196452

Intervention type: DRUG
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT01553201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BoNT)
Description: OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline, 4cc, one time intramuscular administration
Study: NCT03968731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zocular Eyelid System Treatment
Description: Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
Study: NCT01866566

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HBV-3
Description: Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HBV-6
Description: Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: varicella-3
Description: Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: varicella-6
Description: Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
Study: NCT03490851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal + OatWell28CF Int 1
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal + OatWell28CF Int 2
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal + OatWell28CF Int 3
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
Study: NCT02058134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cardioPAT cell saver
Study: NCT00672529

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orthomolecular Therapy or Placebo Comparator
Description: The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orthomolecular Therapy or Placebo Comparator
Description: The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function.
Study: NCT03731364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: 5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: 5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: 5 mg CA-008 (0.05 mg/mL), 10 mg CA-008 (0.1 mg/mL) and 15 mg CA-008 (0.15 mg/mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01759329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: test coffee
Description: test coffee with higher alkyl pyridine content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control coffee
Description: control coffee with regular alkyl pyridine content
Study: NCT00961337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: one dose
Study: NCT00764400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word Retrieval Treatments for Aphasia
Description: Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word Retrieval Treatments for Aphasia
Description: Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
Study: NCT03262532

Intervention type: OTHER
Intervention: Web-base simulator
Description: Training manipulation of TEE using a Web-based simulator

Intervention type: OTHER
Intervention: No web-base simulator
Description: Training manipulation of TEE with out a web-base simulator
Study: NCT00808327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: A single, 15mg, intrathecal dose of bupivacaine.
Study: NCT03240328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: HIV-1 specific chimeric antigen receptor cells
Study: NCT00808327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, fentanyl
Description: A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
Study: NCT03292679

Intervention type: PROCEDURE
Intervention: 3D template
Description: A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.~Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand.
Study: NCT03226223

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Methamphetamine
Description: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Methamphetamine
Description: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
Study: NCT03521687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 30 mg BID
Study: NCT02769845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: drug to be administered

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCD examination
Description: TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCD examination
Description: TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
Study: NCT04037670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SASI bypass
Description: Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
Study: NCT01079962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
Study: NCT02625779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate and Placebo
Study: NCT01079962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
Study: NCT00920595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-9722
Description: Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
Study: NCT00755690

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High/ Low Phosphate diet
Description: Low phosphate diet (750mg/day).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High/ Low Phosphate diet
Description: Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High/ Low Phosphate diet
Description: III. High phosphate diet (2000mg /day).
Study: NCT03106493

Intervention type: OTHER
Intervention: None (observational)
Description: None (observational)

Intervention type: OTHER
Intervention: None (observational)
Description: None (observational)
Study: NCT03490851

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cream of Rice
Description: Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
Study: NCT02625779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate and Cytidine-containing Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate and Creatine-containing Drug
Study: NCT01647854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation in prehospital emergencies
Study: NCT01198665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (Everolimus)
Description: Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
Study: NCT03732755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS Treatment
Description: PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages
Study: NCT01219218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Description: Energy Density - 0.09 mJ/mm2
Study: NCT02491723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Patients with bronchiectasis treated with Azithromycin for three to five days.
Study: NCT01789489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)
Study: NCT03106493

Intervention type: OTHER
Intervention: None (observational)
Description: None (observational)
Study: NCT02792322

Intervention type: DEVICE
Group type: OTHER
Intervention: Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device
Description: Patient's will be having TORS surgery in a seated position
Study: NCT03742401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Traditional open excisional surgery
Study: NCT01482715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
Study: NCT03742401

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU (Echopulse)
Description: High intensity focused ultrasound (HIFU) non invasive intervention
Study: NCT00741143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortification of wheat flour with NaFeEdta
Description: NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fortification of wheat flour with NaFeEdta
Description: NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
Study: NCT02817815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram (ECG)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling from the cephalic vein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling from the femoral vein
Description: Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling from the femoral vein
Description: Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling from the femoral vein
Description: Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling from the femoral vein
Description: Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: First blood sampling from left atrium
Description: Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: First blood sampling from left atrium
Description: Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: First blood sampling from left atrium
Description: Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: First blood sampling from left atrium
Description: Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial stimulation
Description: Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
Study: NCT03512002

Intervention type: DEVICE
Group type: OTHER
Intervention: HIRREM
Description: Technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM
Description: Technology
Study: NCT02817815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial stimulation
Description: Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Second blood sampling from left atrium
Description: After 20min of continuous AF, a blood sampling from left atrium will be done

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Second blood sampling from left atrium
Description: After 20min of continuous AF, a blood sampling from left atrium will be done
Study: NCT02062528

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: highly dosed in EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04056455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule.
Study: NCT01482715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
Study: NCT03427996

Intervention type: PROCEDURE
Intervention: Rotational atherectomy
Description: Percutaneous coronary intervention with rotational atherectomy
Study: NCT03765619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 250 patients will be randomized to receive postoperative Aspirin.
Study: NCT03093714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector
Study: NCT03512002

Intervention type: OTHER
Group type: OTHER
Intervention: Continued Current Care
Description: Continue their current clinical care.